February 6, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2024.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2024.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.02.06 19:38:08 +05'30'

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com

Hyderabad, India, February 06th, 2025: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended December 31, 2024.

Aurobindo Pharma Limited Q3FY25 Consolidated Financial Results

Amount (₹ Cr)	Q3FY25	Q3FY24	% Change YoY	Q2FY25	% Change QoQ
Revenue from Operations	7,979	7,352	8.5%	7,796	2.3%
EBITDA before R&D	2,056	1,975	4.1%	1,954	5.2%
EBITDA margin before R&D	25.8%	26.9%	-110 bps	25.1%	70 bps
EBITDA before Forex and Other Income	1,628	1,601	1.7%	1,566	3.9%
EBITDA Margin (%)	20.4%	21.8%	-138 bps	20.1%	31 bps
PBT before share of P/L of JV, Forex, and Exceptional items	1,248	1,220	2.3%	1,193	4.6%
Net Profit for the period	846	940	-10.0%	817	3.5%

Key Highlights of Q3FY25

- Revenue from Operations increased by 8.5% YoY to ₹ 7,979 Cr with growth across the businesses
- US formulations revenue decreased by 2.3% YoY to ₹ 3,671 Cr (USD 435 million)
- Europe formulations revenue increased by 22.7% YoY to ₹ 2,121 Cr (EUR 236 million)
- Growth Markets revenue increased by 39.3% YoY to ₹ 873 Cr (USD 104 million)
- ARV revenue increased by 71.2% YoY to ₹ 307 Cr (USD 36 million)
- API revenue decreased by 1.6% YoY to ₹ 1,006 Cr (USD 119 million)
- EBITDA before R&D stood at ₹ 2,056 crores with a margin of 25.8%
- EBITDA before Forex and Other Income stood at ₹ 1,628 Cr; EBITDA margin at 20.4%
- Research & Development (R&D including depreciation) spend was ₹ 450 Cr, 5.6% of revenue
- Received final approval for 8 ANDAs (including 1 ANDA previously tentatively approved, now received the final approval) from the USFDA
- Net Profit for the period stood at ₹ 846 Cr
- Basic & Diluted EPS stood at ₹ 14.56 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: *" We are pleased to report our highest-ever quarterly revenue, driven by volume growth from our diverse and expanding product portfolio coupled with new launches. This performance highlights our resilience. Looking ahead, we are enhancing our manufacturing capabilities and ramping up our specialty and injectable business. With these initiatives, we expect notable profitability improvements and are well-positioned to sustain growth and meet our objectives for the year."*

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

Operational Performance (Consolidated)

₹ Cr	Q3FY25	Q3FY24	Y-o-Y (%)	Q2FY25	Q-o-Q (%)
USA	3,671	3,756	-2.3%	3,530	4.0%
Europe	2,121	1,728	22.7%	2,105	0.8%
Growth Markets	873	627	39.3%	812	7.6%
ARV	307	179	71.2%	193	59.1%
Total Formulations	**6,973**	**6,291**	**10.8%**	**6,640**	**5.0%**
Beta-lactam	722	737	-2.0%	837	-13.7%
Non Beta-lactam	284	285	-0.5%	319	-11.0%
Total API	**1,006**	**1,022**	**-1.6%**	**1,156**	**-13.0%**
Consolidated Sales (Ex- Puerto Rico)	**7,979**	**7,313**	**9.1%**	**7,796**	**2.3%**
Puerto Rico	-	39	-	-	
Revenue from operations	**7,979**	**7,352**	**8.5%**	**7,796**	**2.3%**

**includes domestic formulation sales of ₹ 70 Cr in Q3FY25*

Q3FY25: Consolidated Revenue Breakup - Geography & Business wise

Q3FY25





AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

Q3FY25 Performance

Formulations revenue increased by 10.8% YoY to ₹ 6,973 Cr

US Formulations

- US revenue decreased by 2.3% YoY to ₹ 3,671 Cr mainly driven by lower transient product sales and accounted for 46.0% of consolidated revenue
- In USD terms, revenue decreased by 3.7% YoY to USD 435 million
- Filed 4 ANDAs with USFDA during the quarter
- Received final approval for 8 ANDAs (including 1 specialty and injectable ANDA) during the quarter
- As on 31St December 2024, on a cumulative basis, the Company has filed 853 ANDAs with USFDA and received 678 final approvals and 26 tentative approvals
- The Company has launched 7 products during the quarter

Europe Formulations

- Europe revenue increased by 22.7% YoY to ₹ 2,121 Cr and accounted for 26.6% of consolidated revenue
- In Euro terms, revenue increased by 22.1% YoY to EUR 236 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 39.3% YoY to ₹ 873 Cr and accounted for 10.9% of consolidated revenue
- In USD terms, revenue increased by 37.7% YoY to USD 104 million
- Domestic formulation sales for the quarter stood at ₹ 70 Cr

ARV Formulations

- ARV business revenue increased by 71.2% YoY to ₹ 307 Cr accounting for 3.8% of consolidated revenue
- In USD terms, revenue increased by 68.7% YoY to USD 36 million

Active Pharmaceutical Ingredients (API)

- API business revenue decreased by 1.6% Y-o-Y to ₹ 1,006 Cr contributing to 12.6% of consolidated revenue
- In USD terms, revenue declined by 3.0% to USD 119 million

Global Regulatory Filings

Details	Q3FY25	Cumulative Filings as on 31st Dec 2024
US ANDAs (including filings from Aurobindo USA)	4	853
US DMFs (including filings from Eugia and Auro Peptides)	3	297
Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada)	36	4,535
API filings in other key regulated markets (incl. multiple registrations)	60	3,944

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

Final USFDA Approvals Received in Q3FY25

Received by Aurobindo Pharma Limited

#	Product	Strength	Therapy area
1	Metformin Hydrochloride Extended-Release Tablets USP (RLD: FORTAMET®)	500mg and 1000mg	Antidiabetic drugs
2	Clozapine Orally Disintegrating Tablets	12.5 mg, 25 mg, 100 mg, 150 mg and 200 mg	Central Nervous System Drugs
3	Glycopyrrolate Oral Solution	1mg / 5 mL	Anticholinergic agent
4	Cimetidine Tablets	200 mg, 300 mg, 400 mg and 800 mg	Gastrointestinal drugs
5	Metronidazole Gel USP	1%	Anti-infective
6	Pazopanib Tablets	200 mg	Antineoplastics
7	Mometasone Furoate Nasal Spray (OTC)	50 mcg per spray	Antihistamine

Note: * Deutetrabenazine Tablets (FTF) (6 mg, 9 mg and 12 mg) ANDA previously tentatively approved has now received final approval in Dec-24. However, the launch is contingent to settlement date.

Acquired ANDAs in Q3FY25

#	Product	Strength	Therapy area
1	Pravastatin Sodium Tablets USP	10mg, 20mg and 40mg	Cardiovascular Drugs
2	Pravastatin Sodium Tablets USP	80mg	Cardiovascular Drugs

Q3FY25 Earnings Call Details

The Company will host earnings call at **8.30 AM IST on 07th February 2025**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: http://bit.ly/40o2e0k

AUROBINDO PHARMA LIMITED
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha,
Hyderabad – 500 032. Telangana, India

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The Company has 29 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com

Digitally signed by BADDIGAM ADI REDDY
Date: 2025.02.06 19:39:14 +05'30'